Clinical Trials and Research for Women’s Cancers

The gynecologic oncology team at Froedtert & the Medical College of Wisconsin is involved with nationwide groups such as NRG and the GOG Foundation. These groups consist of Gynecologic Oncologists, Medical Oncologists, Pathologists, Radiation Oncologists, and many scientific researchers from around the US and the world.

NRG is a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. Continuous evaluation of our processes is utilized in order to constantly improve the quality of patient care.

To promote this mission, NRG receives support from the National Cancer Institute of the National Institutes for Health. General information on many of these trials for medical professionals and the lay public can be obtained from the NCI clinical trials database.

COGThe GOG Foundation is a nonprofit organization dedicated to transforming the standard of care in gynecologic oncology, conducting clinical and translational research that positively impacts patients through the prevention and treatment of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina, and vulva.

Clinical implications of research findings are disseminated to physicians and health-care professionals around the world, as well as to cancer survivors, their families, support groups, and advocates.

To obtain information regarding any gynecologic clinical trials that our department has open, please contact our research team at 1-855-771-9477 or Email Us.

Open to Enrollment

Type of CancerProtocol ID & Study Title
Any cancer being treated with carboplatinNRG-GY022
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

Keywords: dMMR, DNA mismatch repair, Mismatch Repair Deficient, Early Stage, High Intermediate Rick, newly diagnosed, Pembrolizumab, Immunotherapy
EndometrialERGOMED-ZN-C3-004
A Phase 1b/2 open-label, multicenter study to evaluate the clinical activity, safety, pharmacokinetics (PK), and related biomarkers of ZN-c3 in adult women with recurrent or persistent uterine serous carcinoma (USC). Patients will receive med by mouth for 5 days with 2 days off in a 21 day cycle. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival.

Keywords: Endometrial Cancer, Recurrent
EndometrialGOG-3083/XPORT-EC-042
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter trial of Selinexor in maintenance therapy after systemic therapy for patients with p53 Wild-Type, advanced or recurrent endometrial carcinoma

Keywords: Endometrial Cancer, Primary Cancer, Recurrent Cancer
EndometrialNRG-GY026
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma

Keywords: Endometrial cancer, HER-2 positive
EndometrialNRG-GY028
This study is being done to answer if we can lower the chance of endometrial cancer growing or spreading by adding the drug ipatasertib to treatment with a hormonal drug. The study is divided into two portions, a Phase I portion and a Phase II portion. In the phase I portion of this trial, we want to test the safety of a drug called ipatasertib, by testing different doses of the drug to see which dose is safer for people when given in combination with a fixed dose of a drug called megestrol acetate (MA). The dose of the usual treatment drug stays the same while the dose of the additional drug can be adjusted to determine the best dose. In the Phase II portion of the study we can test how safe the treatment is and how well it works.

Keywords: Endometrial Cancer, Recurrent
OvarianNRG-CC008
A Study to Compare Two Surgical Procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) in Women With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Keywords: BRCA1 Mutations, Salpingectomy, Oophorectomy
Ovary, EndometrialGOG-3082-ACRIVON-ACR-368-201
In this study, ACR-368 is being tested when it is given alone (called monotherapy) and when it is combined with low doses of a chemotherapy medication named gemcitabine (called combination study therapy). The main purpose of this study is to investigate how effective ACR-368 is in treating ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma in a population selected based on subjects who test OncoSignature Positive.

Keywords: Ovarian Cancer, Endometrial Cancer, Platinum Resistant , OncoSignature
Ovarian, primary peritoneal, or fallopian tube cancerNRG-GY027
A Phase 1 study to test adding ipatasertib with the initial standard of chemotherapy, will have a better result in treating the patients with newly diagnosed ovarian cancer. The safety, side effects, and best dose of ipatasertib will also be determined in this study

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms
Ovarian, primary peritoneal, or fallopian tube cancerGOG-3081-PRESERVE-004-MK3475

The study compares two doses of ONC-392 in combination with a fixed dose of pembrolizumab in participants with ovarian cancer who are resistant to platinum-based chemotherapy and have disease progression on line of therapy containing bevacizumab. Results from this study will be used to inform the study design, patient population, and dose selection for future studies in advanced ovarian cancer.

Keywords: Ovarian Cancer, Platinum Resistant, ONC-392
Ovarian, primary peritoneal, or fallopian tube cancerGOG-3073-CORT125134-556 / ROSELLA

This phase 3 study to test the effect of Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer. As there are no currently approved therapies or effective standard of care for heavily pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy and/or bevacizumab, the combination of intermittently administered relacorilant and nab-paclitaxel may demonstrate a substantial improvement without increased toxicity compared with nab-paclitaxel. Patients will receive study treatment until confirmed progressive disease (PD) or unacceptable toxicity. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms
Kidney transplantOBG-IIT-UYAR-HPV-MISP-61451

In this study, we want to learn how people with suppressed immune systems (e.g.-those undergoing an organ transplant) respond to HPV vaccine. We plan to study people who receive the vaccine before they undergo a kidney transplant and those who receive the vaccine after they undergo a kidney transplant to document the difference in the immune response to the vaccine compared to people who are not immune suppressed.


Keywords: Kidney Transplant, Immune Response, Vaccine, HPV

Closed to Enrollment

Type of CancerProtocol ID & Study Title
Cancer PreventionNRG-CC008
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]
AllGOG 136
Tissue Bank: Acquisition of Human Gynecologic Specimens to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
CervicalIovance-C-145-04
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma

Keywords: Cervical cancer, recurrent , metastatic, LN-145, TILs
CervicalADVAXIS ADXS 001-004
Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer

Keywords: Cervical, Recurrent, Metastatic, ADXS11-001, Randomized
CervicalAnti PD-L1 Atezolizumab)
Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Keywords: Cervical Cancer, Atezolizumab, Cisplatin, Chemoradiotherapy, Node Positive, Anti PD-L1
CervicalGOG 263
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Keywords: Stage I/IIA Cervical Cancer
CervicalGOG 274
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL

Keywords: Phase 3, Cervical Cancer, Chemotherapeutic Agent, Toxicity, Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexuality and Reproductive Issues, The Outback Trial
CervicalGOG 265
A Phase II Evaluation of ADXS11-001 in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix

Keywords: Phase II, Cervical Cancer, Recurrent
CervicalGOG 3023/Genmab GCT1015-04
A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer

Keywords: Recurrent Cervical Cancer, Metastatic Cervical Cancer, Squamous Cell, Adenocarcinoma, Adenosquamous Histology, Tisotumab Vedotin, Genmab
CervicalADXS001-02
A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis Immunotherapy to prevent Cervical recurrence)


Keywords: Cervical, ADXS11-001, Adjuvant, High risk, Locally Advanced, AIM2CERV, Phase 3
CervicalNRG-GY006
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Keywords: Randomized, Phase II, Cisplatin, Stage II-IVA
Cervical or Pre-CancerGOG 207
A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)
Cervical or Pre-CancerGOG 219
A Phase III, Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine (IND# 46525) and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis
Cervical or Pre-CancerGOG 227E
Cervix: A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
Cervical or Pre-CancerGOG 240
A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without Bevacizumab versus the Non-Platinum Doublet, Topotecan plus Paclitaxel, with and without Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix

Press Release

Keywords: Recurrent or Persistent Carcinoma of the Cervix
EndometrialSutro- STRO-002-GM1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Keywords: Advance Epithelial Ovarian Cancer, Fallopian Tube, Primary Peritoneal and Endometrial Cancer, Folate Receptor Alpha
Endometrial NRG-GY020
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

Keywords: Endometrial Neoplasms, Endometrioid Carcinoma, Adenocarcinoma, Glandular and Epithelial Neoplasms, Uterine Neoplasms, Female Genital Neoplasms, Urogenital Neoplasms, Ovarian Neoplasms, Pembrolizumab
EndometrialT Regulatory Cells and DNA Methylation in Early Endometrial Cancer Before and After Treatment

Keywords: Endometrial
EndometrialGOG 86P
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/\Ccarboplatin/Temsirolimus and Ixabepilone/Carboplatin/ Bevacizumab as Initial Therapy for Measurable Stage III or IVA,, Stage IVB, or Recurrent Endometrial Cancer
EndometrialGOG 184
A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Cancer
EndometrialGOG 209
A Randomized Phase III Trial of Doxorubicin/ Cisplatin/ Paclitaxel/G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
EndometrialGOG 249
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma

Keywords: Early Stage Endometrial Cancer, Brachytherapy, Radiation Therapy
EndometrialGOG 258
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma

Keywords: Advanced Endometrial Carcinoma
EndometrialGOG-0286B
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Keywords: Endometrial, GOG-0286B, Phase II/III, Recurrent, Stage III, Stage IVA, Stage IVB
EndometrialGOG 286B
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Keywords: Randomized, Phase II, Phase III, Chemotherapeutic, Stage III, Stage IVA, Stage IVb, Endometrial Cancer, Recurrent
Endometrial GOG-3041-AZD9311C00001-DUO
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Keywords: Paclitaxel, Docetaxel, Bevacizumab, Carboplatin, Pembrolizumab, Olaparib
EndometrialGOG LAP 2
A Phase III Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling with Vaginal Hysterectomy and BSO versus Open Laparotomy with Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma, Clinical Stage I, IIA, Grade I, II, III 
EndometrialErgomed/AEZS-108-050
Randomized Controlled Study Comparing AEZS-108 with Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Keywords: Endometrial, Second Line Therapy, Advanced Endometrial Cancer, Recurrent Endometrial Cancer, Metastatic Endometrial Cancer, Doxorubicin, Phase 3
EndometrialGenentech
Maggie: A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 For the Treatment of Recurrent or Persistent Endometrial Carcinoma
Epithelial Ovarian Cancer (EOC)GOG-3036-MERCK-7339-001
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
Epithelial Ovarian, Peritoneal, Fallopian TubeIMMUNOGEN-IMGN853-0417-SORAYA

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Keywords: Platinum resistant, Folate-receptor alpha expression, Phase 3, Antibody-drug conjugate, mirvetuximab soravtansine, IMGN853, Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, MIRV, FRα
Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CELSION-201-17-201
Phase I-II Study Evaluating the Dosing, Safety, Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms
VIN 3/ HPV, Pre-cancer, HPVINOVIO- HPV-201
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA® 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
Keywords: Pre-Cancer, Vulvar, VIN, HPV
Ovarian and Endometrial Leap DEK-DKK1-P204
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer
Keywords: Epithelial Ovarian Cancer, Epithelial Endometrial Cancer, High-Grade Serous, Low-Grade Serous, Mucinous, Endometrioid, Clear Cell, Undifferentiated or Unclassified, DKN-01, Recurrent
Ovarian and EndometrialTesaro TSR-042 4010-01-001
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD1 Monoclonal Antibody in Patients with Advance Solid tumors
Keywords: Ovarian, Endometrial, Platinum-Resistant, Tesaro, TSR-042, Advanced, 4010-01-001, Phase 1, Anti-PD1 Monoclonal Antibody, Solid Tumors
OvarianSpringworks NIR-OGT-201
This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms, Granulosa cell tumor
OvarianNRG-GY007
A Phase I/II STUDY OF Ruxolitinib With Front-Line Neoadjuvant And Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Keywords: Ruxolitinib, Neoadjuvant, Epithelial Ovarian
OvarianNRG -GY021
The study is intended to determine whether olaparib plus tremelimumab has adequate safety in the study population and to compare the progression-free survival (PFS) duration of olaparib monotherapy versus olaparib plus tremelimumab in women with recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
Keywords: Ovarian, Recurrent Ovarian Cancer, Platinum-Sensitive Ovarian Cancer, Olaparib, PARP inhibitor, Tremelimumab, CTLA4 immune checkpoint inhibitor, Immunotherapy, high-grade serous, high-grade endometrioid, BRCA1 or BRCA2 mutation
OvarianCORT125134-552 (Corcept)
A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Keywords: Recurrent Ovarian Cancer, Platinum Resistant Ovarian Cancer, Ovarian, Fallopian Tube, Primary Peritoneal, Nab-Paclitaxel, Relacorilant, Corcept, CORT125134-552
OvarianGOG 3005 A Phase 3 Placebo-
Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PRO00024744)

Keywords: Ovarian, Primary, Maintenance, Untreated, PARP Inhibitor, PARP, Veliparib, Serous
OvarianGOG 182
A Phase III Randomized Trial of Paclitaxel and Carboplatin versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma
OvarianGOG 186H
A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysis NSC # 729968, BB-IND # 13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Keywords: Recurrent, Fallopian tube, Ovarian Epithelial, Primary Peritoneal, Viral Therapy, Chemotherapy, Phase II
OvarianGOG 212
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy

Keywords: Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
OvarianGOG 213
A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with Bevacizumab, followed by Bevacizumab and secondary cytoreduction surgery in platinum-sensitive, recurrent ovarian, fallopian tube and peritoneal primary cancer

Keywords: Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
OvarianGOG 218
Ovarian and Primary Peritoneal: A Phase III Trial of Carboplatin and Paclitaxel plus Placebo versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab (NSC #704865, IND# 7921) Followed by Placebo versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian or Primary Peritoneal or Fallopian Tube Cancer
OvarianGOG 225
Can Diet and Exercise Modulate Ovarian, Fallopian Tube or Peritoneal Cancer Progression-Free Survival?

Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Weight Change, Healthy Lifestyle
OvarianGOG 235
A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy

Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Tumor Marker
OvarianGOG 241
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)

Keywords: Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Oxaliplatin
OvarianGOG 244
The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients

Keywords: Cervical Cancer, Endometrial Cancer, Vulvar Cancer, Lymphedema, Quality of Life
OvarianGOG 252
Ovarian: A Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agents(s): Bevacizumab (NSC #704865, IND# 7921)
OvarianGOG 267
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Quality of Life
OvarianGOG 268
A Phase II Evaluation of Temsirolimus in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary

Keywords: Clear Cell Carcinoma of the Ovary
OvarianGOG 255
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate + OPT-821 Versus OPT-821 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer who are in Second or Third Complete Remission

Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Vaccine
OvarianGOG 261
A Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary

Keywords: Recurrent or Persistent Ovarian, Sarcoma
OvarianGOG 262
A Randomized Phase III Trila of every 3 weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Caboplatin with or without Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

Keywords: Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
OvarianGOG 272
Pilot Study of Standard Therapy for Prevention of Nausea Associated with First Line Post-operative Intraperitoneal Chemotherapy

Keywords: Stage II, III or IV Ovarian, Fallopian Tube, or Primary Peritoneal
OvarianGOG 273
Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
OvarianGOG 281
A randomized phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer or peritoneal cancer

Keywords: Low-Grade, Low-Grade Serous, Recurrent
OvarianGOG 3001
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, GOG 3001-Multi-Center Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers (Amgen Protocl #2010129)

Keywords: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
OvarianGOG 3003
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 (IND#78,416) in Combination with Pegylated Liposomal Doxorubicin (PLD) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Keywords: Recurrent, Persistent, Ovarian, Fallopian Tube, Primary Peritoneal
OvarianGOG 3004
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy

Keywords:Olaparib, Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
OvarianGOG 3005 A Phase 3 Placebo-
Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PRO00024744)

Keywords: Ovarian, Primary, Maintenance, Untreated, PARP Inhibitor, PARP, Veliparib, Serous
Ovarian GOG-3018-VBL-VB-111-701
The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for theTreatment of Recurrent Platinum-Resistant Ovarian Cancer

Keywords: Recurrent Ovarian cancer, Platinum resistant ovarian cancer, Ovarian cancer, Ovarian carcinoma, Epithelial ovarian cancer, paclitaxel
OvarianGOG 3013
A Phase 3, Multicenter, Randomized, Open-label Study Of Avelumab (MSB0010718C) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-resistant/Refractory Ovarian Cancer

Keywords: Ovarian, Platinum Resistant, Platinum Refractory, Avelumab, Randomized
Ovarian GOG 3048
Mersana First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Keywords: Platinum-Resistant, Mersana Therapeutics, XMT-1536 (upifitamab rilsodotin), Antibody-Drug Conjugate (ADC), Early Phase, High Grade Serous, First in Human, Measurable Disease
OvarianGOG-3059
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial
OvarianGOG 9927
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888) and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Keywords: Recurrent Ovarian, Primary Peritoneal, Fallopian Tube
OvarianGOG 9928
A Phase I Study of Intraperitoneal Egen-001 Administered in Combination with Pegylated Liposomal-Doxorubicin in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Keywords: Recurrent, Persistent, Epithelial Ovarian, Fallopian Tube, Primary Peritoneal
OvarianGOG 3011/Immunogen
Forward 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor α–positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer Or Fallopian Tube Cancer

Keywords: Forward 1, Phase 3, Mirvetuximab Soravtansine, IMGN853, Immunogen, Folate receptor α-positive, Epithelial, Ovarian, Primary Peritoneal, Fallopian tube
OvarianGOG 3012 - TESARO
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Keywords: HRD-positive, advanced Ovarian, Niraparib, Randomized, Double-blind
OvarianNRG-GY001
A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum


Keywords: Ovarian, Recurrent, Cabozantinib, Clear cell
OvarianAmgen 386 Study 20090508
A Phase 3, Randomized, Double-blind Trial of Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Following a Prior Platinum-Containing Regimen
OvarianCelsion Gen-1 Phase I Neoadjuvant Ovarian
A Phase I Study of the Safety and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Keywords: Phase 1, Ovarian, Neoadjuvant
OvarianGYN49 AZD1775
A Multicenter Randomized Phase II Study of AZD1775 plus Chemotherapy versus Chemotherapy Alone in Patients with Platinum-Resistant TP53-Mutated Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (GYN 49)

Keywords: Platinum Resistant, TP53, Recurrent, Phase II
OvarianMERCK
A Study of MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer
OvarianMERCK 3475-100
A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer (KEYNOTE -100)

Keywords: Ovarian, Keynote, Pembrolizumab, Recurrent
OvarianNRG-CC002
Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers

Keywords: QOL, Quality of Life, Surgery, 70+
OvarianNRG-GY004
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

Keywords: Phase III, Olaparib, Cediranib, Platinum-Based, Ovarian
OvarianNRG-GY005
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Keywords: Randomized, Cediranib, Olaparib, Ovarian, Platinum Resistant
OvarianAcerta ACE-ST-208
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Recurrent Ovarian Cancer (PRO 25546) is now open to patient accrual.

Keywords: Ovarian Cancer, Phase 2, Recurrent, Pembrolizumab, ACP-196
OvarianJanssen R&D Protocol ET743-OVC-3006
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced Relapsed Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Keywords: Randomized, Open Label, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Relapsed, Phase 3, Recurrent Ovarian Cancer, Doxil, Yondelis, BRCA, Platinum Sensitive, Third Line
OvarianAstraZeneca-Light Study D0816L00003
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at least 1 prior line of platinum-based chemotherapy

Keywords: Ovarian, Parp, Olaparib, Light Study, Recurrent, Platinum Sensitive, High Grade, Endometriod, Serous
Ovarian or Pre-cancerGOG 214
A Phase II Double Blind Randomized Trial Evaluating the Biologic Effect OF Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer

Keywords: High risk for Ovarian, Prevention
OvarianSOLO3
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations

Keywords: BRCA1/2, Olaparib, Recurrent, Ovarian
OvarianThe OVAL Study
A Randomized, Controlled, Double-Arm, Double Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Other Study Identifiers: VB-111-701, GOG-3018
Keywords: Recurrent Ovarian Cancer, Platinum Resistant Ovarian Cancer, Ovarian, Ovarian Carcinoma, Epithelial Ovarian Cancer, Paclitaxel, VB-111, GOG-3018
OvarianGOG-3020 / ENGOT-ov45/NCRI/ATHENA
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients.
Keywords: Ovarian, Parp, Rucaparib, ATHENA y, Nivolumab, Maintenance, primary therapy, Front-Line Platinum-Based
OvarianIIT-Uyar Merck 3475-250
Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer
Keywords: Suboptimal Cytoreduced, Ovarian, Pembrolizumab, First Line, Epithelial, Nonrandomized
Ovarian HOFFMANN-LAROCHE-YO40482
A Phase Ib Study of Cobimetinib Administered In Combination with Niraparib, with or without Atezolizumab, to Patients with Advanced Platinum-Sensitive Ovarian Cancer

Keywords: Ovarian Neoplasms, Ovarian Epithelial Carcinoma, Endocrine Gland Neoplasms, Female Genital Neoplasms, Urogenital Neoplasms, Glandular and Epithelial Neoplasms
Ovarian, primary peritoneal, or fallopian tube cancerSTRO-002-GM2
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer Ovarian, primary peritoneal, or Fallopian Tube Cancer

Keywords: STRO-002, Phase 1, Bevacizumab, Refractory, Platinum Resistant, Dose Expansion, Anti-Folate Receptor Alpha Antibody Drug Conjugate, Advanced Epithelial Ovarian Cancer, Measurable Disease, High Grade Serous
Ovarian, primary peritoneal, or fallopian tube cancerNRG-GY023
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Keywords: Durvalumab, Olaparib, or Cediranib, Recurrent Platinum Resistant, MEDI4736, Parp Inhibitor, Monoclonal Antibodies, VEGF, High Grade Serous, Grade 3 Endometrioid or Clear Cell Carcinoma, BRCA1 or BRCA2 Mutation
Ovarian, primary peritoneal, or fallopian tube cancerGOG-3049-MER-XMT1536-3-UP-NEXT
Phase 3, multi-center randomized study of XMT-1536 (upifitamab rilsodotin) in patients with tumors expressing high levels of NaPi2b, focusing on patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC) including fallopian tube and primary peritoneal cancer. This study will assess the progression free survival (the length of time that participants live without their disease getting worse) for participants with ovarian cancer with high NaPi2b.

Keywords: Ovarian cancer, platinum sensitive, recurrent cancer, randomized
Recurrent Clear Cell Ovarian CancerNRG-GY016
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary. (Single Arm Study)

Keywords: Ovarian, Clear Cell, Recurrent Clear Cell, Pembrolizumab, MK-3475 , Epacadostat , Immunotherapy, Phase 2, Recurrent, Persistent Disease, Monoclonal Antibodies, PDL-1, Measurable Disease
UterineGOG 277
A Phase III Randomized Trial of Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma

Keywords: Uterine, Sarcoma, Leiomyosarcoma.
Uterine Serous CarcinomaERGOMED-ZN-C3-004
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma

Keywords: Uterine Serous Carcinoma, Cystadenocarcinoma, Serous, Neoplasms